HTLV-1: The Fundamental Proteins for ATL
DOI:
https://doi.org/10.58445/rars.1245Keywords:
cancer, HTLV-1, genetics, ATLAbstract
HTLV-1 is an enveloped delta retrovirus common in rural areas with neglected health care systems. About 10 million people are affected globally. It is most often diagnosed in areas near the equator. It is mostly spread through blood transfusions but can also be spread by breastfeeding and unprotected sex. Breastfeeding has an infection rate of only around 5%. Unprotected sex has the highest probability of resulting in HTLV-1 infection. While sharing needles will lead to infection, plasma and industrial blood products can not transmit the virus. It is the sole cause of ATL (Adult T-Cell Leukemia). Symptoms of ATL are swollen lymph nodes, enlarged livers and/or spleen, and rashes. To test for HTLV-1, doctors use: Enzyme Linked Immunoassay, Particle Agglutination Assay, Western Blotting, Immunofluorescence Assay, Radioimmunoprecipitation Assay, and PCR. The Western Blot test is the most commonly used test.. This cancer has a <50% survival rate as it is not curable yet. There are many proteins involved in this pathogenesis. Each of these proteins have their own unique way of contributing to leukemogenesis or the life cycle of the virus. Tax is a transactivator and can mutate cells, Rex is essential for early stages, regulates expression and carries important viral messages, HBZ encodes many necessary accessory genes and is key to leukemogenesis. Studying HTLV-1 is important because it can lead to treatments and cures for this cancer. This review is meant to focus on HTLV-1 genes Tax, Rex, and HBZ and other associated proteins that can play a role in leukemogenesis, specifically ATL, and T-Cell Dysfunction and discuss possible treatment options.
References
Ahmadi Ghezeldasht, S., Shirdel, A., Assarehzadegan, M. A., Hassannia, T., Rahimi, H., Miri, R., & Rezaee, S. A. R. (2013). Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL). Iranian Journal of Basic Medical Sciences, 16(3), 179–195.
Bazarbachi, A., & Hermine, O. (1996). Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology: Official Publication of the International Retrovirology Association, 13 Suppl 1, S186-190. https://doi.org/10.1097/00042560-199600001-00028
Currer, R., Van Duyne, R., Jaworski, E., Guendel, I., Sampey, G., Das, R., Narayanan, A., & Kashanchi, F. (2012). HTLV tax: A fascinating multifunctional co-regulator of viral and cellular pathways. Frontiers in Microbiology, 3, 406. https://doi.org/10.3389/fmicb.2012.00406
Durer, C., & Babiker, H. M. (n.d.). Adult T-Cell Leukemia [Statpearls]. Retrieved January 28, 2024, from https://www.ncbi.nlm.nih.gov/books/NBK558968/#:~:text=and%20Patient%20Education-,Adult%20T%20cell%20leukemia%20is%20primarily%20caused%20by%20HTLV%2D1,lifetime%20risk%20for%20developing%20ATL
Eusebio-Ponce, E., Anguita, E., Paulino-Ramirez, R., & Candel, F. J. (2019). HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Revista Espanola De Quimioterapia: Publicacion Oficial De La Sociedad Espanola De Quimioterapia, 32(6), 485–496.
Kchour, G., Rezaee, R., Farid, R., Ghantous, A., Rafatpanah, H., Tarhini, M., Kooshyar, M.-M., El Hajj, H., Berry, F., Mortada, M., Nasser, R., Shirdel, A., Dassouki, Z., Ezzedine, M., Rahimi, H., Ghavamzadeh, A., de Thé, H., Hermine, O., Mahmoudi, M., & Bazarbachi, A. (2013). The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology, 10, 91. https://doi.org/10.1186/1742-4690-10-91
Mahgoub, M., Yasunaga, J.-I., Iwami, S., Nakaoka, S., Koizumi, Y., Shimura, K., & Matsuoka, M. (2018). Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 115(6), E1269–E1278. https://doi.org/10.1073/pnas.1715724115
Marino-Merlo, F., Balestrieri, E., Matteucci, C., Mastino, A., Grelli, S., & Macchi, B. (2020). Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview. Pathogens (Basel, Switzerland), 9(5), 342. https://doi.org/10.3390/pathogens9050342
Matsuo, M., Ueno, T., Monde, K., Sugata, K., Tan, B. J. Y., Rahman, A., Miyazato, P., Uchiyama, K., Islam, S., Katsuya, H., Nakajima, S., Tokunaga, M., Nosaka, K., Hata, H., Utsunomiya, A., Fujisawa, J.-I., & Satou, Y. (2022). Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nature Communications, 13(1), 2405. https://doi.org/10.1038/s41467-022-30029-9
Matsuoka, M., & Green, P. L. (2009). The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology, 6, 71. https://doi.org/10.1186/1742-4690-6-71
Nakano, K., & Watanabe, T. (2012). HTLV-1 Rex: The courier of viral messages making use of the host vehicle. Frontiers in Microbiology, 3, 330. https://doi.org/10.3389/fmicb.2012.00330
Nakano, K., & Watanabe, T. (2022). Tuning Rex rules HTLV-1 pathogenesis. Frontiers in Immunology, 13, 959962. https://doi.org/10.3389/fimmu.2022.959962
Ratner, L. (2022). A role for an HTLV-1 vaccine? Frontiers in Immunology, 13, 953650. https://doi.org/10.3389/fimmu.2022.953650
Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., Hasegawa, Y., & Yamano, Y. (2018). Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. The New England Journal of Medicine, 378(6), 529–538. https://doi.org/10.1056/NEJMoa1704827
Zhao, T. (2016). The Role of HBZ in HTLV-1-Induced Oncogenesis. Viruses, 8(2), 34. https://doi.org/10.3390/v8020034
Downloads
Posted
Categories
License
Copyright (c) 2024 Sanvi Nadgir
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.